Key result
Sacubitril/valsartan therapy led to prompt amelioration of heart function and a decrease in NYHA class at 30 days in two patients with HFrEF.
Why the study?
Does sacubitril/valsartan improve heart function and symptoms in patients with HFrEF in daily clinical practice?
Case Report (n=2)
Does sacubitril/valsartan improve heart function and symptoms in patients with HFrEF in daily clinical practice?
Sacubitril/valsartan can be safely and effectively used in real-world clinical practice to rapidly improve heart function and symptoms in HFrEF patients with multiple comorbidities.
Supports sacubitril/valsartan in select HFrEF cases; leaves open optimal real-world use.
Following the results of the PARADIGM-HF trial, the European Society of Cardiology (ESC) guidelines recommend sacubitril/valsartan to replace ACE inhibitors in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy and who fit trial criteria. However, the optimal use of sacubitril/valsartan in clinical practice needs further investigation. We report here the cases of 2 patients with HFrEH successfully treated with sacubitril/valsartan in our daily practice. Both subjects presented multiple comorbidities and received an implantable cardioverter defibrillator in primary prevention. In both patients, therapy with sacubitril/valsartan led to prompt (30 days) amelioration of heart function, with a corresponding decrease in NHYA class and without any relevant safety issue.
No takes yet. Share an insight, caveat, or question.
Eugenio Roberto Cosentino (2017) conducted a case report in Heart failure with reduced ejection fraction (HFrEF) (n=2). Sacubitril/valsartan was evaluated on Amelioration of heart function and decrease in NYHA class. Sacubitril/valsartan therapy led to prompt amelioration of heart function and a decrease in NYHA class at 30 days in two patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: